STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How coverage developed
First report from STAT
Story updateHeadline updated
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page on .
Signal breakdown
CurrentWire ranked this story 66.7 of 100 in the snapshot this page was rendered from.
- Freshness
- 30.7 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (4).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.